Skip to main content

Share story

AI

Agents, meet the Figma canvas

Agents, meet the Figma canvas Image: Primary
Figma announced the beta release of its MCP server. The server brings Figma into the developer workflow to help large language models generate code informed by designs. Claude Code, Codex and other MCP clients can generate and modify design assets that link to a design system. The new use_figma tool allows agents to operate on the canvas using a team's components and variables. An existing generate_figma_design tool converts HTML from live apps and websites into editable Figma layers. The tools complement each other when designs fall out of sync with code. Skills written as markdown files guide how agents build on the Figma canvas. They encode steps, guidelines and a team's specialized knowledge. No plugin or code is required to author a skill. The foundational figma-use skill gives agents a shared understanding of Figma from its structure to its core principles. Several example skills from practitioners launched alongside the beta. The capability is currently available for free during the beta period. It will become a usage based paid feature in the future.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Figma and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.